At the same time, DKN-01 in combination with pembrolizumab showed a favorable safety profile, while the anti-tumor efficacy was superior mainly in anti-PD-1/PD-L1-naïve patients with high expression of DKK1 [87]. Here, DKK1 is linked to neoplasm.